Find a company
Search the SBRI Healthcare and NHS Cancer Programme Innovation Open call portfolio.
If you would like further information on any of the companies listed in the Directory please contact the SBRI Healthcare PMO by email sbri@lgcgroup.com or tel: +44 20 8843 8125.
We would be happy to make introductions to the companies or provide any further feedback you require.
At a glance
Directory search results
Sensixa
| Project | Care for adaptive living and learning with interactive sensing for children and adults with learning difficulties |
|---|---|
| Description |
Sensixa is developing of a novel, miniaturised sensor either as ear-worn sensor or wrist band, with a seamlessly integrated mobile app to be used to predict potential adverse events and adapts to individual care needs to ensure improved access to diagnosis and care |
| Funding | £ 80,667 |
| Competition | Competition 7 - Telehealth and Telecare for People with Learning Disabilities |
| Competition Date | May 2014 |
| Categories | Ear |
| Health Innovation Network Partner | South London AHSN |
| Website | http://sensixa.com/ |
Oncascan
| Project | The development of the lymphocyte genome sensitivity (LGS) test for the diagnosis of cancer |
|---|---|
| Description |
Oncascan is introducing a step change in cancer diagnosis and management. The patented Lymphocyte Genome Sensitivity (LGS) blood test uses increased sensitivity to ultra-violet induced DNA damage of lymphocytes from cancer patients to distinguish between those with and without the disease. The project aims to develop a practical system for use in clinical laboratories to improve the management of patients with suspected cancers. Before embarking on invasive and costly investigations, patients found to not have cancer can be identified with the obvious reduction for them in anxiety, discomfort, time off work and clinical risk. |
| Funding | £ 884,551 |
| Competition | Competition 5 - Improving Diagnosis and Treatment Management of Cancer |
| Competition Date | September 2013 |
| Health Innovation Network Partner | Oxford AHSN |
Astrimmune
| Project | Implementation and Validation of a novel test for pancreatic and other gastrointestinal cancers based on shed tumour cells in the blood |
|---|---|
| Description |
Astrimmune is developing a diagnostic test for pancreatic and other gastrointestinal cancers based on detection and profiling of shed tumour cells in the blood. Requiring only 6ml of blood, the test provides unique insight into surface markers and gene expression of pancreatic cancer cells; isolating these cells from blood allows detection before metastasis can occur. Survival rates of pancreatic cancer could be improved dramatically if early detection were possible. |
| Funding | £ 912,650 |
| Competition | Competition 5 - Improving Diagnosis and Treatment Management of Cancer |
| Competition Date | September 2013 |
| Categories | Cancer , Oral & gastrointestinal |
| Health Innovation Network Partner | East Midlands AHSN |
| Website | https://uk.linkedin.com/company/astrimmune |